[go: up one dir, main page]

NO973933L - Vaskulær endotelvekstfaktor B - Google Patents

Vaskulær endotelvekstfaktor B

Info

Publication number
NO973933L
NO973933L NO973933A NO973933A NO973933L NO 973933 L NO973933 L NO 973933L NO 973933 A NO973933 A NO 973933A NO 973933 A NO973933 A NO 973933A NO 973933 L NO973933 L NO 973933L
Authority
NO
Norway
Prior art keywords
vascular endothelial
polypeptides
growth factor
endothelial growth
vegf
Prior art date
Application number
NO973933A
Other languages
English (en)
Other versions
NO973933D0 (no
Inventor
Ulf Eriksson
Birgitta Olofsson
Kari Alitalo
Katri Pajusola
Original Assignee
Ludwig Inst Cancer Res
Helsingfors University Licensi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO973933(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/469,427 external-priority patent/US5607918A/en
Application filed by Ludwig Inst Cancer Res, Helsingfors University Licensi filed Critical Ludwig Inst Cancer Res
Publication of NO973933D0 publication Critical patent/NO973933D0/no
Publication of NO973933L publication Critical patent/NO973933L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO973933A 1995-03-01 1997-08-27 Vaskulær endotelvekstfaktor B NO973933L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39765195A 1995-03-01 1995-03-01
US08/469,427 US5607918A (en) 1995-03-01 1995-06-06 Vascular endothelial growth factor-B and DNA coding therefor
US08/569,063 US5928939A (en) 1995-03-01 1995-12-06 Vascular endothelial growth factor-b and dna coding therefor
PCT/US1996/002957 WO1996026736A1 (en) 1995-03-01 1996-03-01 Vascular endothelial growth factor-b

Publications (2)

Publication Number Publication Date
NO973933D0 NO973933D0 (no) 1997-08-27
NO973933L true NO973933L (no) 1997-09-01

Family

ID=27410265

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973933A NO973933L (no) 1995-03-01 1997-08-27 Vaskulær endotelvekstfaktor B

Country Status (14)

Country Link
US (5) US5928939A (no)
EP (1) EP0814827B1 (no)
JP (2) JP3275024B2 (no)
CN (1) CN1146440C (no)
AT (1) ATE245437T1 (no)
AU (1) AU741856B2 (no)
CA (1) CA2211687C (no)
DE (1) DE69629181T2 (no)
DK (1) DK0814827T3 (no)
ES (1) ES2202432T3 (no)
NO (1) NO973933L (no)
NZ (1) NZ305091A (no)
PT (1) PT814827E (no)
WO (1) WO1996026736A1 (no)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
DK0751992T3 (da) * 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
DE69630442T2 (de) * 1995-03-02 2004-08-19 Amrad Operations Pty. Ltd., Richmond Ein neuartiger wachstumsfaktor und eine genetische sequenz, die für diesen codiert
US7160991B1 (en) 1995-03-02 2007-01-09 Ludwig Institute For Cancer Research Vascular endothelial growth factor polypeptides
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
EP0873348A4 (en) * 1995-06-06 2000-11-08 Human Genome Sciences Inc GROWTH FACTOR 3 OF THE HUMAN VASCULAR ENDOTHELIUM
US7727761B2 (en) * 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
DK0848755T4 (da) 1995-09-08 2011-05-23 Genentech Inc VEGF relateret protein
ATE290077T1 (de) 1995-09-29 2005-03-15 Univ Siena Regulierte gene und ihre verwendungen
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
WO1997017442A1 (en) 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
DE69734359T2 (de) 1996-08-23 2006-07-06 Ludwig Institute For Cancer Research Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
AU5439998A (en) * 1996-12-06 1998-06-29 Zymogenetics Inc. Vascular endothelial growth factor
ZA9711456B (en) * 1996-12-20 1998-06-30 Ludwig Inst Cancer Res VEGF-B/receptor complex and uses thereof.
DE69830320T2 (de) 1997-03-07 2006-02-02 The Wistar Institute Of Anatomy And Biology Verwendung von Adenoviralen Vektoren, die PDGF oder VEGF exprimieren, ZUR HEILUNG VON GEWEBSDEFEKTEN UND ZUR INDUZIERUNG DER HYPERVASKULITÄT IN SÄUGERGEWEBEN
WO1998049300A2 (en) * 1997-04-25 1998-11-05 Collateral Therapeutics Truncated vegf-related proteins
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
AU767662B2 (en) 1998-02-06 2003-11-20 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
WO2000027879A1 (en) 1998-11-10 2000-05-18 Ludwig Institute For Cancer Research Platelet-derived growth factor d, dna coding therefor, and uses thereof
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
JP2002535006A (ja) * 1999-01-29 2002-10-22 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 血小板由来増殖因子／血管内皮増殖因子様増殖因子ｈとその利用法
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
JP2002537769A (ja) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
AU3614700A (en) * 1999-03-03 2000-09-21 Ludwig Institute For Cancer Research Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities
AU4662400A (en) * 1999-04-26 2000-11-10 Helsinki University Licensing Ltd Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
EP1183358A1 (en) * 1999-06-07 2002-03-06 Edwards Lifesciences Corporation Targeted angiogenesis
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
CA2380072C (en) * 1999-07-28 2007-07-10 John Cooke Nicotine in therapeutic angiogenesis and vasculogenesis
US7371392B2 (en) * 2000-02-02 2008-05-13 The United States Of America As Represented By The Department Of Health And Human Services Cd40 ligand adjuvant for respiratory syncytial virus
AUPQ568100A0 (en) * 2000-02-16 2000-03-09 Amrad Operations Pty. Limited A method for producing recombinant molecules
JP4981229B2 (ja) 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
AUPQ592100A0 (en) * 2000-02-29 2000-03-23 Council Of The Queensland Institute Of Medical Research, The A method of treatment and prophylaxis
US20030104977A1 (en) * 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
NZ522014A (en) * 2000-05-17 2007-03-30 Ludwig Inst Cancer Res Methods for detecting for the presence of tumor cells and for screening for anti-tumor agents
WO2002007514A2 (en) * 2000-07-26 2002-01-31 Ludwig Institute Of Cancer Research Glycosylated vegf-b and method for increasing the amount of soluble vegf-b
MXPA02003434A (es) * 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
AU2001296521A1 (en) * 2000-10-02 2002-04-15 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
EP1330252A4 (en) * 2000-11-01 2007-12-26 Ludwig Inst Cancer Res IN VIVO STIMULATION OF ANGIOGENIC ACTIVITY
JP2004537260A (ja) * 2000-12-07 2004-12-16 サンガモ バイオサイエンシーズ， インコーポレイテッド ジンクフィンガータンパク質による血管新生の調節
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20070111944A1 (en) * 2001-02-16 2007-05-17 Scrofani Sergio D B Purification of vascular endothelial growth factor-B
US20070050857A1 (en) * 2001-02-28 2007-03-01 Hayward Nick K Method of treatment and prophylaxis
AU2002303261A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
MXPA03009408A (es) 2001-04-13 2004-01-29 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
CA2444624A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20030170786A1 (en) * 2001-04-13 2003-09-11 Rosen Craig A. Vascular endothelial growth factor 2
US20050043227A1 (en) * 2001-04-24 2005-02-24 Veerle Compernolle Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
EP1581241A4 (en) * 2001-06-20 2005-11-09 Ludwig Inst Cancer Res STIMULATION OF VASCULARIZATION WITH VEGF-B
WO2003002609A2 (en) * 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1425580A4 (en) * 2001-07-12 2006-03-29 Ludwig Inst Cancer Res LYMPHATIC ENDOTHELIAL CELLS AND METHODS THEREOF
US7217570B2 (en) 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20030113324A1 (en) 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
CA2429483A1 (en) * 2002-05-17 2003-11-17 Amrad Operations Pty Ltd. Immunointeractive molecules
EP1912069A3 (en) 2002-06-05 2008-07-09 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
WO2003104415A2 (en) * 2002-06-05 2003-12-18 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
US20030232439A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7479270B2 (en) 2002-07-23 2009-01-20 Vegenics Limited Methods and compositions for activating VEGF-D and VEGF-C
AU2003296338A1 (en) * 2002-12-05 2004-06-30 Case Western Reserve University Cell-based therapies for ischemia
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
SI1660057T1 (sl) 2003-08-27 2012-10-30 Ophthotech Corp Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
US20060003008A1 (en) 2003-12-30 2006-01-05 Gibson John W Polymeric devices for controlled release of active agents
AU2005218570A1 (en) * 2004-03-02 2005-09-15 Ludwig Institute For Cancer Research Method for inhibiting tumor formation and growth
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
DE602005011943D1 (de) * 2004-04-08 2009-02-05 Sangamo Biosciences Inc Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
CA2575901C (en) * 2004-08-02 2015-01-27 Amrad Operations Pty. Ltd. A method of treating cancer comprising a vegf-b antagonist
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
ATE553122T1 (de) * 2005-02-28 2012-04-15 Sangamo Biosciences Inc Antiangiogene methoden und zusammensetzungen
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
CA2604441A1 (en) * 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
EP1919944B1 (en) * 2005-08-15 2011-03-23 Vegenics Pty Ltd Modified vegf and pdgf with improved angiogenic properties
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
DK2018184T3 (da) 2006-05-17 2013-10-28 Ludwig Inst Cancer Res Anti-vegf-b-antistof til behandling eller forebyggende behandling af type 2-diabetes eller metabolisk syndrom
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
EA200901301A1 (ru) * 2007-06-06 2010-06-30 Домантис Лимитед Полипептиды, вариабельные домены антител и антагонисты
US7819579B2 (en) * 2007-11-26 2010-10-26 Schmulenson Harold K Radiation sensing device and holder
WO2009075565A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Methods for controlling vasculogenesis
KR101642846B1 (ko) 2007-12-26 2016-07-26 백시넥스 인코포레이티드 항-ｃ35 항체 병용 치료 및 방법
US20110150900A1 (en) * 2008-04-09 2011-06-23 Ludwig Institute For Cancer Research Regulation of fatty acid transporters
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
KR101335203B1 (ko) * 2010-03-26 2013-11-29 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
RU2477529C2 (ru) * 2011-04-28 2013-03-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к эндотелиальной синтазе оксида азота человека
IL294463A (en) 2013-07-12 2022-09-01 Iveric Bio Inc Methods for treating or preventing eye conditions
DK3082860T3 (da) * 2013-12-18 2021-01-25 Csl Ltd Fremgangsmåde til behandling af sår
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
US10745454B2 (en) * 2018-01-31 2020-08-18 Seyed Mohsen Asghari Method of synthesizing antagonist peptides for cell growth
CN109337931A (zh) * 2018-11-02 2019-02-15 东北师范大学 Vegfb基因的应用及vegfb肿瘤诱导和肿瘤抑制动物模型的构建方法
CN110777146A (zh) * 2019-11-28 2020-02-11 南通大学 一种pdgfb启动子活性报告质粒的构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
DK0751992T3 (da) * 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
DE69630442T2 (de) * 1995-03-02 2004-08-19 Amrad Operations Pty. Ltd., Richmond Ein neuartiger wachstumsfaktor und eine genetische sequenz, die für diesen codiert
EP0873348A4 (en) * 1995-06-06 2000-11-08 Human Genome Sciences Inc GROWTH FACTOR 3 OF THE HUMAN VASCULAR ENDOTHELIUM

Also Published As

Publication number Publication date
HK1008485A1 (en) 1999-07-30
ATE245437T1 (de) 2003-08-15
US7341996B2 (en) 2008-03-11
CN1146440C (zh) 2004-04-21
ES2202432T3 (es) 2004-04-01
JP2000228982A (ja) 2000-08-22
PT814827E (pt) 2003-11-28
JP3297687B2 (ja) 2002-07-02
AU741856B2 (en) 2001-12-13
JP3275024B2 (ja) 2002-04-15
WO1996026736A1 (en) 1996-09-06
EP0814827B1 (en) 2003-07-23
US20050064493A1 (en) 2005-03-24
NZ305091A (en) 1998-11-25
DE69629181D1 (de) 2003-08-28
US20030170253A1 (en) 2003-09-11
EP0814827A1 (en) 1998-01-07
JPH10510718A (ja) 1998-10-20
AU5302196A (en) 1996-09-18
CA2211687A1 (en) 1996-09-06
DK0814827T3 (da) 2003-11-10
EP0814827A4 (en) 1999-11-10
US5840693A (en) 1998-11-24
CA2211687C (en) 2011-05-24
US5928939A (en) 1999-07-27
NO973933D0 (no) 1997-08-27
US6331301B1 (en) 2001-12-18
DE69629181T2 (de) 2004-05-13
CN1176603A (zh) 1998-03-18

Similar Documents

Publication Publication Date Title
NO973933D0 (no) Vaskulær endotelvekstfaktor B
DK1749836T3 (da) Rekombinant vaskulær endothelcellevækstfaktor D
BR9711795A (pt) Peptìdeos tendo propriedades antiproliferativas
RU94046367A (ru) Днк, хозяйская клетка, способ получения белка, белок, фармацевтический препарат, антитело, применение антитела
ATE391778T1 (de) Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen
DK1356052T3 (da) Produktion af hele antistoffer i prokaryotiske celler
DK0713529T3 (da) Vækst-/differentieringsfaktor af TGF-beta-familien
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DE69941791D1 (de) Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen
AU2002305450A1 (en) Proteomimetic compounds and methods
DE69229681D1 (de) Ein protein, das spezifische dna-strukturen erkennt, und seine verwendungen
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
DE60042793D1 (de) Inhibitor des hepatozytwachstumsfaktoraktivators und dessen verwendung zur modulation von angiogenese und herzvaskularisierung
DK0714441T3 (da) Rekombinante Cladosporium herbarum allergener
WO2001025437A3 (en) Growth factor polypeptides and nucleic acids encoding same